In the wake of Vioxx, the public wants safer drugs. But tougher standards need to come with new tools for managing risk, or innovation will stall. That's the adverse event no-one's talking about.
Dec 1, 2004
There's nothing like a product withdrawal to put the pharmaceutical industry under the microscope. Following Merck's decision to withdraw Vioxx from the market, a flurry of reports in the US media suggested a need to re-examine and overhaul everything from the drug approval process, to direct-to-consumer advertising, to the way pharma handles R&D. Our challenge as an industry is to use the Vioxx case as a catalyst for making thoughtful improvements to our current practices—improvements that build on the many things we are doing right.